Register for email alerts and news feeds:
This journal | BMJ Group
rss
Published Online First: 3 February 2006. doi:10.1136/jcp.2005.029603
Journal of Clinical Pathology 2006;59:373-736
Copyright © 2006 by the BMJ Publishing Group Ltd & Association of Clinical Pathologists.

ORIGINAL ARTICLE

Serum HER-2 concentration in patients with primary breast cancer

S-Y Kong, J H Kang, Y Kwon, H-S Kang, K-W Chung, S H Kang, D H Lee, J Ro and E S Lee

Research Institute and Hospital, National Cancer Centre, Gyeonggi-do, Korea

Correspondence to:
Correspondence to:
Dr Eun Sook Lee
Centre for Breast Cancer, National Cancer Centre, 809, Madu-dong, Ilsan-gu, Goyang-si, Gyeonggi-do 411-769, Republic of Korea; eunsook{at}ncc.re.kr

Objective: To evaluate whether serum HER-2/neu (HER-2) concentration is a valid index of HER-2 status in women with primary breast cancer, and to establish a normal reference range for serum HER-2 concentration in Korean women.

Methods: Serum HER-2 concentration was measured and immunohistochemistry (IHC) and fluorescence in situ hybridisation (FISH) carried out on tissue samples from 86 consecutive female patients. The results of the three datasets were compared. The cut off value of HER-2 concentration was determined from the mean +2SD values derived from the serum of 93 healthy volunteers.

Results: The IHC and FISH data were significantly correlated (p<0.01), but neither showed significant correlation with the serum HER-2 data. The cut off value of serum HER-2 was 10.2 µg/l, and the serum HER-2 concentration of patients with primary breast cancer ranged from 5.0 to 17.5 µg/l. Only five patients had a serum HER-2 value above the cut off value.

Conclusions: Serum HER-2 concentration cannot be substituted for IHC or FISH to evaluate HER-2 status, nor can it be used as a diagnostic tumour marker in primary breast cancer, considering the low prevalence of serum HER-2 elevation.

Abbreviations: FISH, fluorescence in situ hybridisation; IHC, immunohistochemistry

Keywords: HER-2/neu; immunohistochemistry; fluorescence in situ hybridisation; primary breast cancer


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

This article has been cited by other articles:

  • Leary, A. F., Hanna, W. M., van de Vijver, M. J., Penault-Llorca, F., Ruschoff, J., Osamura, R. Y., Bilous, M., Dowsett, M. (2009). Value and Limitations of Measuring HER-2 Extracellular Domain in the Serum of Breast Cancer Patients. JCO 27: 1694-1705 [Abstract] [Full Text]  

This Article

Services
Citing Articles
Google Scholar
PubMed
Topic Collections
Bookmark with

Register for free content

The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

Pathology jobs

Pathology jobs